Adipotide is a synthetic peptide made in the laboratory. It is also known as Fat-Targeted Proapoptotic Peptide (FTPP). FTPP refers to a class of fat-targeted proapoptotic peptides designed to target adipose tissue vasculature. Adipotide is one of them. In preclinical trials on non-human research subjects, it has shown promising benefits in addressing adipose tissues.
Adipose tissues refer to fat tissues in test subjects. While targeting adipose tissues in subjects in preclinical trials, the adipotide peptide may influence the patterns associated with removing fat tissue. This quality has shown potential for affecting the biomarkers linked with weight loss, insulin production, and glucose levels in test subjects, as evidenced in the trial on mice.
The working mechanism of the Adipotide peptide is known as Apoptosis. Apoptosis refers to the process through which fat is removed from research subjects. Clinical trials on animals demonstrated that adipotide may block blood supply to the vasculature of fat tissue. Such blockage may lead to the death of fat cells, and subsequently to their gradual removal from the body of animals or non-human research subjects.
The potential benefits of adipotide peptide observed during preclinical trials are as follows:
Research trials of 4 weeks conducted on organisms have found an impact on adipose tissue. The trials further demonstrated that such an impact occurred due to its working mechanism, which modulates the patterns of blood flow to the fat tissues. Without blood flow, fat tissues may ultimately die, as evidenced in the trials on organisms. Later, such fatty tissues are removed from the test subjects’ bodies, as was the case during the 4-week trials on monkeys.
Another study shows that the Adipotide peptide may influence insulin signaling mechanisms in research subjects during clinical investigations. When the dose of adipotide peptide was administered to non-human research subjects during the trials, the subjects showed that their bodies had effectively utilized glucose. Such effective utilization of blood glucose also led to a balanced sugar level in test subjects in the clinical trials. [2]
Regulating appetite control is another potential benefit witnessed in the preclinical trials on research subjects. The trials further explored the possibility that such appetite regulation may not occur directly but is linked to secondary factors in test subjects. For instance, changes in energy levels and metabolic rate patterns may indirectly decrease food intake by regulating appetite in non-human subjects during the trials.
Like a coin, everything has two sides: bright and dark. In the case of Adipotide, its dark side appears insignificant compared to its bright side. However, we will still explore its negative side to inform researchers to take effective research protocols. Here are the commonly occurring side effects of the adipotide peptide:
Note: These are minor or mild side effects that may be easily managed by ensuring adherence to research protocols and taking precautionary measures
